Journey Medical Corporation ( (DERM) ) has released its Q3 earnings. Here is a breakdown of the information Journey Medical Corporation presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Journey Medical Corporation is a commercial-stage pharmaceutical company specializing in the marketing and sales of FDA-approved prescription products for dermatological conditions. Based in Scottsdale, Arizona, the company is known for its efficient sales model and a portfolio of eight branded drugs.
In its third-quarter 2025 earnings report, Journey Medical Corporation announced a 21% increase in net revenues compared to the same period last year, reaching $17.6 million. The company highlighted the significant growth of Emrosi™, a key product in its portfolio, which saw a 146% increase in total prescriptions from the previous quarter.
Key financial metrics from the report include a gross margin of 67.4%, a slight decrease from the previous year due to one-time adjustments in 2024. Selling, general, and administrative expenses rose by 6% to $12.1 million, primarily due to the commercialization of Emrosi. Despite a net loss of $2.3 million, the company showed improvement in EBITDA, which was negative $0.5 million compared to negative $1.0 million in the previous year, and a positive adjusted EBITDA of $1.7 million.
Journey Medical’s strategic focus on Emrosi has been validated by recent clinical data presented at a dermatology conference, confirming its efficacy over competitors. The company has expanded payer access significantly, enhancing its market presence and potential for future growth.
Looking ahead, Journey Medical Corporation remains optimistic about leveraging its established dermatology infrastructure and the growing market acceptance of Emrosi to drive future revenue growth and operational leverage.